Ortoma (ORT) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 reached SEK 38.7 million, up from SEK 4.4 million year-over-year, driven by milestone payments and product sales.

• EBITDA improved to SEK 19.5 million from SEK -2.6 million, and net income after financial items was SEK 16.3 million versus SEK -5.6 million last year.

• Progress made on international partnerships and barter facilities, with Millstolpe setting key milestones for regulatory and commercial objectives.

• Business case for year-end includes effectiveness at quality benchmarks and expansion in hearing and implantation solutions.

• New CEO, Fredrik Strömberg, appointed effective May 15, 2025, to lead commercialization and growth.

Significant events and developments

• Supplementary 510(k) FDA submission for Custom OTS™ Hip and CE certification for OTS™ Hip Guide, enabling US and EU market entry.

• Secured deals with organizations such as the American Academy of Orthopedic Surgeons and Japanese Society for Replacement Arthroplasty.

• Achieved over 400 hearing implantations, indicating operational scale and product adoption.

• Milestone payments received: USD 167,500 (~SEK 1.7 million) and USD 2 million (~SEK 22.1 million).

• Appointment of new CEO, Fredrik Strömberg, effective May 15, 2025.

Segment performance

• Notable activity in hearing and implantation segments, with broad product quality and detailed case studies.